TY - JOUR
T1 - Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma
T2 - basic principles and recent advances
AU - Wang, Xiang
AU - Yuan, Zijun
AU - Li, Zhengbo
AU - He, Xinyu
AU - Zhang, Yinping
AU - Wang, Xingyue
AU - Su, Jiahong
AU - Wu, Xu
AU - Li, Mingxing
AU - Du, Fukuan
AU - Chen, Yu
AU - Deng, Shuai
AU - Zhao, Yueshui
AU - Shen, Jing
AU - Yi, Tao
AU - Xiao, Zhangang
N1 - This work was supported by the National Natural Science Foundation of China (Grants: 81972643) and the Joint Funds of the Southwest Medical University and Luzhou (Grants: 05/00140026, 05/00160006) and Science and Technology Department of Sichuan Province (Grants: 2023NSFSC0717).
Publisher Copyright:
© 2024 Wang, Yuan, Li, He, Zhang, Wang, Su, Wu, Li, Du, Chen, Deng, Zhao, Shen, Yi and Xiao.
PY - 2024/2/15
Y1 - 2024/2/15
N2 - The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.
AB - The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.
KW - tumor-infiltrating lymphocytes (TILs)
KW - hepatocellular carcinoma (HCC)
KW - immunotherapy
KW - signaling pathway
KW - TILs preparation
KW - targeting neoantigens
UR - http://www.scopus.com/inward/record.url?scp=85186219633&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2024.1354313
DO - 10.3389/fimmu.2024.1354313
M3 - Journal article
C2 - 38426090
AN - SCOPUS:85186219633
SN - 1664-3224
VL - 15
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1354313
ER -
